MannKind's Furosix Ramp And Pediatric Afrezza Uptake Face First Real Test After Catalyst Sweep

MannKind arrives at its third-quarter report having done the hard part of 2026 on paper. Pediatric Afrezza won approval, the Furosix ReadyFlow auto-injector cleared the FDA, and the inhaled nintedanib program posted a clean Phase 1b readout. The question now is whether those wins show up in the numbers quickly enough to justify a year of deliberately heavy spending, and this quarter offers the first full look at a business shifting from launch preparation to execution.

The Street is looking for a loss of $0.08 per share on revenue of about $105.6 million. That revenue figure would represent healthy growth of roughly 28.5% from the $82.1 million posted a year ago, but it is a step down from the $109.4 million reported last quarter. That sequential dip is not necessarily a warning sign. Management indicated that the second quarter marked the peak for manufacturing revenue, so some cooling in collaboration and services income, which jumped to $35 million last quarter, is already expected. The real story lies in what replaces it. On the bottom line, the swing from a $0.03 profit a year ago to an expected loss reflects the cost of the build-out, and this quarter carries extra baggage: a $45 million contingent value right payout with roughly $16 million of associated expense, plus about $2.2 million per quarter in new intangible amortization. A reported loss that looks ugly may largely reflect those known items rather than any operational slippage.

Furosix is the most important line to scrutinize. Management reaffirmed, but did not raise, its full-year guidance of $110 million to $120 million, which implies roughly $75 million in second-half sales after about $38 million in the first half. That is a steep climb, and it depends partly on how smoothly inventory converts from the older OnBody infuser to ReadyFlow, which was slated to launch by the end of August. Second-quarter sales of $22.2 million, helped by a record nephrology prescriber count after an earlier sales force reorganization stumble, provided a credible base. A third-quarter figure that moves meaningfully above that level would validate the guide; a flat result would put enormous pressure on the fourth quarter and invite doubts about whether the range survives.

On Afrezza, the pediatric launch started briskly, with a third of the top 100 pediatric rapid-acting insulin prescribers and all 20 priority accounts already writing, and roughly 450 new prescribers overall. The catch is that more than half of pediatric scripts were flowing through a cash program, so early volume does not translate cleanly into revenue until payer coverage firms up, a process management framed as stretching to year-end. Adult Afrezza, which softened as resources were redirected, was described as bottoming in the second or third quarter. Evidence that the adult decline has stabilized while paid pediatric coverage begins to expand would strengthen the narrative considerably. Royalty revenue, whose growth slowed to 4% last quarter, is another spot where further deceleration would chip at the profit cushion.

The market has not given MannKind much credit for its catalyst sweep. Shares have fallen 8.4% since the last report while the S&P 500 was essentially flat, and at $3.50 the stock sits below its 200-day moving average of $3.75, in the lower half of a post-earnings range between $2.90 and $4.40. Sentiment, however, has turned noticeably more constructive, moving from mildly bearish ahead of last quarter to clearly bullish now. That gap between improving sentiment and lagging price suggests investors want to believe but are waiting for proof.

That proof comes down to Furosix. If third-quarter sales show the second-half ramp is underway and ReadyFlow conversion is proceeding cleanly, the heavy losses read as investment with a visible payoff. If the ramp looks stalled, the reaffirmed guidance becomes the center of the debate, and the catalyst story risks being overshadowed by the cost of chasing it.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.